Behind The Scenes Of Pharma Mergers And Acquisitions - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Behind The Scenes Of Pharma Mergers And Acquisitions


Pharmaceutical Technology Europe
Volume 22, Issue 9

In summary


The author says…
It is likely that a new round of mergers and acquisitions are set to take place in the pharmaceutical industry. Although such tie-ups can improve pipelines in the short-term and improve marketing potential, many of the mergers are also influenced by pressure from outside parties who believe bigger organisations will provide better financial return to investors. The financial effort required for the next round of mergers among the top ten companies will need to be huge. As has already been seen, targeted companies tend to hold out for improved offers rather than accept an initial approach. Takeovers will have to be planned meticulously since companies will need to determine how they borrow the billions of dollars required, absorb the costs involved and yet still deliver on their promises to investors.

References

1. KPMG, "Global M&A: Outlook for Pharmaceuticals" (2009). http://www.kpmgeuropellp.eu/

2. Chemistry World, "Pharma's year of merger mania" (2009). http://www.rsc.org/

3. A. Pollack, "Roche Agrees to Buy Genentech for $46.8 Billion" (2009). http://www.nytimes.com/

4. Drug, Discovery & Development, "Roche Leaves PhRMA" (2009). http://www.dddmag.com/

5. Wall Street Journal, "Pharmaceutical Merger Bonanza: $500 Million of Fees in 3 Months" (2009). http://blogs.wsj.com/

6. R. Breitman, "Pharma Mergers Boom Despite Global Credit Woes" (2008). http://www.law.com/

7. Anon, "King Completes Acquisition of Alpharma. King Pharmaceuticals" (2008). http://www.kingpharm.com/

8. A. Pollack, "Genentech Urges a Rebuff to Roche" (2009). http://www.nytimes.com/

9. S. Cage, "Roche seen upping $42 billion Genentech bid after rebuff" (2009). http://www.reuters.com/

10. Anon, "Roche and Genentech reach a friendly agreement to combine the two organizations and create a leader in healthcare innovation" (2009). http://www.roche.com/

11. T. Staton, "Merger costs weigh on Pfizer, Roche" (2010). http://www.fiercepharma.com/

12. L. Johnson, "Pfizer CEO: Wyeth Merger Will Bring What's Needed" (2010). http://www.dddmag.com/

13. Wall Street Journal, "Checking the Math on Job Cuts at Pfizer and Wyeth" (2009). http://blogs.wsj.com/

14. E. Silverman, "Merck And Pfizer Plan 900 Job Cuts" (2010). http://www.pharmalot.com/

15. R. Waters, "Genentech culture intact after Roche takeover" (2010). http://articles.sfgate.com/

16. T. Staton, "Sanofi isn't alone in eyeing Genzyme deal" (2010). http://www.fiercepharma.com/


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology Europe,
Click here